Expression of PDE4D Gene in Ovarian Cancer Based on Oncomine and the Regulation of Sanguinarine

Yue DENG; Dan ZOU; Abdelkerim Barh TOUNA; Lihua YANG

doi:10.12259/j.issn.2095-610X.S20220303

Volume 43 Issue 3

Mar. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(3): 1-6

Yue DENG, Dan ZOU, Abdelkerim Barh TOUNA, Lihua YANG. Expression of PDE4D Gene in Ovarian Cancer Based on Oncomine and the Regulation of Sanguinarine[J]. Journal of Kunming Medical University, 2022, 43(3): 1-6. doi: 10.12259/j.issn.2095-610X.S20220303

Citation:

Yue DENG, Dan ZOU, Abdelkerim Barh TOUNA, Lihua YANG. Expression of PDE4D Gene in Ovarian Cancer Based on Oncomine and the Regulation of Sanguinarine[J]. Journal of Kunming Medical University, 2022, 43(3): 1-6. doi: 10.12259/j.issn.2095-610X.S20220303

Citation:

PDF( 907 KB)

Expression of PDE4D Gene in Ovarian Cancer Based on Oncomine and the Regulation of Sanguinarine

doi: 10.12259/j.issn.2095-610X.S20220303

Dept. of Gynecology，The 2nd Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650101，China

Received Date: 2022-01-02
Available Online: 2022-02-18
Publish Date: 2022-03-22

Abstract

Abstract

Objective To investigate the expression and clinical significance of PDE4D in ovarian cancer by excavating gene information in Oncomine and explore the effect of sanguinarine on PDE4D by cells experiment. Methods PharmMapper was used to find the targets matched with the pharmacodynamic groups of sanguinarine. The gene information about PDE4D in ovarian cancer research was collected in Oncomine, and the expression level was analyzed. The A2780 and SKOV3 ovarian carcinoma cells were divided into control group and sanguinarine group. CCK8 and RT-qPCR were used to detect the effects of sanguinarine on the proliferation and PDE4D mRNA expression of A2780 and SKOV3 cells. Results PDE4D was the target matched with the pharmacodynamic group of sanguinarine. There were 6 studies referred to PDE4D in ovarian cancer and normal sample collected in the Oncomine. The expression of PDE4D in tumor tissues was significantly higher than that in normal （P < 0.05）. The cell experiments showed that compared with the control group, the proliferation of A2780 and SKOV3 cells was significantly inhibited and the expression of PDE4D mRNA was decreased in the sanguinarine group, with statistical significance （P < 0.05）. Conclusions PDE4D gene may play a role in the occurrence and development of ovarian cancer, and sanguinarine can inhibit the growth of ovarian cancer cells, which may be related to the down-regulation of PDE4D expression.
- Ovarian cancer,
- PDE4D,
- Oncomine,
- Sanguinarine

FullText(HTML)

References(26)

References

[1]	Zhang Q,Madden N E,Wong A S T,et al. The role of endocrine G protein-coupled receptors in ovarian cancer progression[J]. Frontiers in Endocrinology,2017,8:66.
[2]	Hsien Lai S,Zervoudakis G,Chou J,et al. PDE4 subtypes in cancer[J]. Oncogene,2020,39(19):3791-3802. doi: 10.1038/s41388-020-1258-8
[3]	Fu C,Guan G,Wang H. The anticancer effect of sanguinarine:A review[J]. Current Pharmaceutical Design,2018,24(24):2760-2764. doi: 10.2174/1381612824666180829100601
[4]	Liu X, Ouyang S, Yu B, et al. Pharm Mapper server: a web server for potential drug target identification using pharmacophore mapping approach[J]. Nucleic Acids Research, 2010, 38 （Web Server issue）: W609-614.
[5]	Rhodes D R,Yu J,Shanker K,et al. ONCOMINE:a cancer microarray database and integrated data-mining platform[J]. Neoplasia (New York,NY),2004,6(1):1-6. doi: 10.1016/S1476-5586(04)80047-2
[6]	Yu H,Touna A,Yin X,et. al. Identification of differentially expressed genes and biological pathways in sanguinarine-treated ovarian cancer by integrated bioinformatics analysis[J]. Pharmacognosy Magazine,2021,17(73):106-113. doi: 10.4103/pm.pm_111_20
[7]	李京辉,朱明,曲海,等. miR-490-3p调控SW1990胰腺癌细胞上皮间充质转化[J]. 昆明医科大学学报,2021,42(3):10-17. doi: 10.12259/j.issn.2095-610X.S20210305
[8]	Lin D C,Xu L,Ding L W,et al. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers[J]. Proceedings of the National Academy of Sciences of the United States of America,2013,110(15):6109-6114. doi: 10.1073/pnas.1218206110
[9]	Pullamsetti S S,Banat G A,Schmall A,et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF[J]. Oncogene,2013,32(9):1121-1134. doi: 10.1038/onc.2012.136
[10]	Rahrmann E P,Collier L S,Knutson T P,et al. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen[J]. Cancer Research,2009,69(10):4388-4397. doi: 10.1158/0008-5472.CAN-08-3901
[11]	Liu F,Ma J,Wang K,et al. High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma[J]. Journal of Cancer,2019,10(25):6252-6260. doi: 10.7150/jca.35443
[12]	Cao B,Wang K,Liao J M,et al. Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation[J]. eLife,2016,5:e15978. doi: 10.7554/eLife.15978
[13]	Muntean D M,Sturza A,Pavel I Z,et al. Modulation of cancer metabolism by phytochemicals-a brief overview[J]. Anti-cancer Agents in Medicinal Chemistry,2018,18(5):684-692. doi: 10.2174/1871520617666171114102218
[14]	梁宏. 基于生物信息学挖掘卵巢癌顺铂耐药机制及潜在治疗药物 [D]. 昆明: 昆明医科大学硕士论文, 2016.
[15]	Yu Y,Luo Y,Fang Z,et al. Mechanism of sanguinarine in inhibiting macrophages to promote metastasis and proliferation of lung cancer via modulating the exosomes in A549 cells[J]. OncoTargets and Therapy,2020,13:8989-9003. doi: 10.2147/OTT.S261054
[16]	Rahman A,Pallichankandy S,Thayyullathil F,et al. Critical role of H(2)O(2) in mediating sanguinarine-induced apoptosis in prostate cancer cells via facilitating ceramide generation,ERK1/2 phosphorylation,and Par-4 cleavage[J]. Free Radical Biology & Medicine,2019,134:527-544.
[17]	Khan A Q,Mohamed E A N,Hakeem I,et al. Sanguinarine induces apoptosis in papillary thyroid cancer cells via generation of reactive oxygen species[J]. Molecules (Basel,Switzerland),2020,25(5):1229. doi: 10.3390/molecules25051229
[18]	Fan H N,Chen W,Peng S Q,et al. Sanguinarine inhibits the tumorigenesis of gastric cancer by regulating the TOX/DNA-PKcs/ KU70/80 pathway[J]. Pathology,Research and Practice,2019,215(11):152677.
[19]	Gong X,Chen Z,Han Q,et al. Sanguinarine triggers intrinsic apoptosis to suppress colorectal cancer growth through disassociation between STRAP and MELK[J]. BMC Cancer,2018,18(1):578. doi: 10.1186/s12885-018-4463-x
[20]	Ma Y,Yu W,Shrivastava A,et al. Sanguinarine inhibits pancreatic cancer stem cell characteristics by inducing oxidative stress and suppressing sonic hedgehog-Gli-Nanog pathway[J]. Carcinogenesis,2017,38(10):1047-1056. doi: 10.1093/carcin/bgx070
[21]	Sarkhosh-Inanlou R,Molaparast M,Mohammadzadeh A,et. al. Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin-resistant ovarian cancer (A2780) cells[J]. Chemical Biology & Drug Design,2020,95(2):215-223.
[22]	Zhang S,Leng T,Zhang Q,et. al. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway[J]. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie,2018,102:302-308.
[23]	赵洪波,王妍妍,冷天艳,等. 血根碱对紫杉醇耐药卵巢癌A2780/taxol细胞生长及化疗敏感性影响的研究[J]. 实用妇产科杂志,2018,34(4):268-272.
[24]	Zhang H,Kong Q,Wang J,et al. Complex roles of cAMP-PKA-CREB signaling in cancer[J]. Experimental Hematology & Oncology,2020,9(1):32.
[25]	Huang H,Wang Y,Kandpal M,et al. FTO-dependent N (6)-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling[J]. Cancer Research,2020,80(16):3200-3214. doi: 10.1158/0008-5472.CAN-19-4044
[26]	Gong S,Chen Y,Meng F,et al. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis[J]. Cell Proliferation,2018,51(5):e12474. doi: 10.1111/cpr.12474

Relative Articles(20)

Relative Articles

[1]	Qinglan PENG, Jialu LUO, Jiayi YU, Kaixin WANG, Fang WU, Chuanzhi XU. Signal Mining and Analysis of Adverse Events of Azithromycin Based FAERS Database. Journal of Kunming Medical University, 2024, 45(8): 1-8.
[2]	Lizhu ZHAO, Ying DONG, Yue DENG, Lihua YANG. Correlation between Epithelial Cell Related Genes and Prognosis of Patients with Ovarian Cancer based on Single Cell Sequencing. Journal of Kunming Medical University, 2024, 45(4): 9-16. doi: 10.12259/j.issn.2095-610X.S20240402
[3]	Xingfen WANG, Yue DENG, Lihua YANG. Construction of Lipid Metabolism-Related Gene Prognostic Model and Immunoinfiltration Analysis of Ovarian Cancer. Journal of Kunming Medical University, 2024, 45(4): 17-25. doi: 10.12259/j.issn.2095-610X.S20240403
[4]	Yaping JIANG, Hongying YANG, Haohan WANG, Xianling Ning, Xielan YANG. Effect of Different Intestinal Surgical Methods on Prognosis of Patients with Intestinal Invasive Epithelial Ovarian Cancer. Journal of Kunming Medical University, 2023, 44(1): 85-90. doi: 10.12259/j.issn.2095-610X.S20230109
[5]	Yijun YAN, Hongying YANG, Hongping ZHANG, Zheng LI, Yue JIA, Min ZHAO. Screening and Validation of Potential Prognostic Markers of Cervical Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database. Journal of Kunming Medical University, 2023, 44(8): 14-26. doi: 10.12259/j.issn.2095-610X.S20230808
[6]	Yangyang LIAN, Hongping YUE, Ya DUAN, Hongwen HU, Fang LUO. The Role of miRNA-15a/16 in Regulating Bmi-1 Protein in Ovarian Cancer Resistance to Cisplatin Chemotherapy. Journal of Kunming Medical University, 2023, 44(12): 25-31. doi: 10.12259/j.issn.2095-610X.S20231204
[7]	Yanfei WANG, Juan MA, Yunqiao YANG. Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure. Journal of Kunming Medical University, 2022, 43(11): 136-140. doi: 10.12259/j.issn.2095-610X.S20221117
[8]	Xiaoyan YANG, Chunguang HAO, Zhijian ZHANG. Mechanisms of Progesterone on Proliferation and Migration of Human Ovarian Cancer Cells via HOXA9. Journal of Kunming Medical University, 2022, 43(10): 35-42. doi: 10.12259/j.issn.2095-610X.S20221022
[9]	Lixiu XU, TUERXUN Meiliban, YAKUFU Kereman. Studies on Cisplatin Resistance of miR-181a in Ovarian Cancer Cells. Journal of Kunming Medical University, 2022, 43(1): 20-25. doi: 10.12259/j.issn.2095-610X.S20220131
[10]	Liu Jun , Xu Bing Ying . . Journal of Kunming Medical University, 2019, 40(08): 112-115.
[11]	Ni Hui Xia , Zhao Wei , Hu Ji Hong , Wang Tao . Application Effects of Three-dimensional Printing Technology Based on CT Angiography in the Education of Interventional Neuroradiology. Journal of Kunming Medical University, 2018, 39(01): 136-139.
[12]	Zhang Lu , Lv Le Chun , Wu Yan Rui , Yuan Fang , Tang Wen Yu , Zou Xian Qiang , Li Chun Yin , Zhao Min . Parallel Mining of Gene Expression Differences of Nucleotide Excision Repair Gene XPA in Human Skin Microarrays based on GEO Database. Journal of Kunming Medical University, 2018, 39(03): 38-41.
[13]	Hu Wan Qin , Zhao Hong Bo , Liang Hong , Zhao Qing Hua , Yang Li Hua . Analysis of Differential Expression Genes and Signal Pathways Associated with Cisplatin Resistant Ovarian Cancer. Journal of Kunming Medical University, 2017, 38(06): 97-101.
[14]	Hu Yu Chong , Lu Jing Kun , Cui Meng Yao . . Journal of Kunming Medical University, 2017, 38(03): 27-30.
[15]	Wang Chun Long , Han Dan , Wen Liang . Research Progress of Mesothelin in Tumor Diagnosis and Treatment. Journal of Kunming Medical University, 2017, 38(09): 134-139.
[16]	Yang Han . . Journal of Kunming Medical University,
[17]	Zhang Yan . . Journal of Kunming Medical University,
[18]	Yang Li Hua . . Journal of Kunming Medical University,
[19]	. Application of Direct Amplification for Various Samples in Establishing DNA Database. Journal of Kunming Medical University,
[20]	Liang Rong Bi . . Journal of Kunming Medical University,